Save Product
Product Details
Synonyms
DPP4, ADABP, ADCP2, CD26, DPPIV, TP103
Source
Human DPPIV, Fc Tag (DP4-H5266) is expressed from human 293 cells (HEK293). It contains AA Asn 29 - Pro 766 (Accession # NP_001926.2).
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the N-terminus.
The protein has a calculated MW of 112.3 kDa. The protein migrates as 90-116 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human DPPIV, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Human DPPIV, Fc Tag (Cat. No. DP4-H5266) at 2 μg/mL (100 μL/well) can bind MERS S1 protein, His Tag (Cat. No. S1N-M52H5) with a linear range of 0.039-0.156 μg/mL (Routinely tested).
Protocol
Bioactivity
Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC). The specific activity is >3500 pmol/min/µg (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Dipeptidyl peptidase IV
- Category：
- Approved Drugs：
41 Details
- Drugs in Clinical Trials：
40 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
